Royalty Report: Drugs, Disease, Therapeutic – Collection: 4036


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Diabetes Treatment

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4036

License Grant
The Company has a research and development Agreement with the Licensor, whereby the Parties have established a collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 6042

License Grant
We established a collaborative alliance with a leading Danish manufacturer of medicinal chewing gum.  The Licensee has a research and development Agreement with the Licensor whereby the Parties have established collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity. The Agreement includes certain milestone payments required of the Licensee upon the Licensor's completion of various development phases.

IPSCIO Record ID: 209493

License Grant
In consideration of Licensors performance, to date, under the Agreement and its agreement herein to relinquish all of its rights in and to the Licensee Products.
License Property
The rights relate to the sale of Metformin in the United States.  Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.
Field of Use
This agreement is for the pharmaceutical industry.

Metformin is used in the treatment of diabetes.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.